Press Release

India Immunology Drugs Market to Grow with a CAGR of 7.08% through 2029

Increasing prevalence of immunological disorders and innovative & new product launches is expected to drive the India Immunology Drugs Market growth in the forecast period, 2025-2029.


According to TechSci Research report, “India Immunology Drugs Market -Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029”, the India Immunology Drugs Market stood at USD 2.65 Billion in 2023 and is anticipated to grow with a CAGR of 7.08% in the forecast period, 2025-2029. The India Immunology Drugs Market is primarily driven by several key factors. The increasing prevalence of immunological disorders, such as rheumatoid arthritis and multiple sclerosis, is one major driving force.

Additionally, India's robust pharmaceutical industry and its capacity for high-volume generic drug production contribute significantly to market growth. Advances in biologic drug development and a growing understanding of immunological diseases have also allowed for more targeted and effective therapies, further propelling market expansion. Lastly, increased healthcare expenditures and a growing awareness about immunological disorders among the public are also contributing to the growth of this market.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "India Immunology Drugs Market.


India, with its vast population and burgeoning middle class, presents a significant and lucrative market for immunology drugs. These drugs, specifically designed to modulate the immune system, play a pivotal role in the treatment of various diseases, including autoimmune disorders, infectious diseases, and cancers. Over the past decade, the Indian immunology drugs market has witnessed exponential growth, fueled by expanding healthcare infrastructure and improved access to medical services.

Both established pharmaceutical giants and emerging local companies are making notable inroads into this promising market. Several factors contribute to its growth, including the increasing awareness about autoimmune diseases, rising healthcare expenditure, and the advent of biosimilars. Additionally, the prevalence of immunology-related diseases, such as rheumatoid arthritis, psoriasis, and Crohn’s disease, has been on the rise, further driving the demand for these drugs. However, challenges persist in the form of the high cost of immunology drugs and the complexity associated with drug development. The pricing of these medications often renders them unaffordable for the average Indian consumer, limiting access. Moreover, the development of new drugs requires substantial resources and time, making it a high-risk endeavor for market players.

Nonetheless, the advent of biosimilars, which are essentially more affordable versions of biologic drugs, has the potential to disrupt the market and increase accessibility. Indian pharmaceutical companies, leveraging their expertise in generic drugs, are at the forefront of biosimilar development, contributing to the market's dynamics.

The Indian government's focus on improving healthcare infrastructure and making healthcare more affordable presents a unique opportunity for the immunology drugs market. Policies such as Ayushman Bharat, the world's largest government-funded healthcare program, are expected to drive the demand for these drugs. The COVID-19 pandemic has further highlighted the critical role of immunology in disease management and prevention, amplifying the spotlight on immunology drugs. This has resulted in increased awareness and demand, further bolstering the market's growth prospects.

While the Indian immunology drugs market faces certain obstacles, the overall outlook remains positive. With continued investment in healthcare and the surge in the development of biosimilars, the market is poised for substantial growth in the coming years. Despite the challenges, the potential of the Indian immunology drugs market is immense, and its strategic importance on the global stage is indisputable. The continuous exploration of innovative solutions and collaborations will be instrumental in unlocking its full potential.

The India Immunology Drugs Market is segmented into drug class, indication, end user, regional distribution, and company.

Based on end user, hospitals, being the primary healthcare facilities, play a crucial role in the administration and usage of immunology drugs. With their extensive reach and capacity to cater to a large number of patients, hospitals experience a higher demand and consumption of immunology medications. This is mainly due to the fact that hospitals are equipped with specialized medical professionals and advanced infrastructure, making them ideal for the treatment and management of various immunological conditions. In addition to providing comprehensive medical care, hospitals often collaborate with research institutes and pharmaceutical companies to stay updated with the latest advancements in immunology. This ensures that patients receive the most effective and innovative therapies available.

Furthermore, hospitals serve as important hubs for clinical trials and research studies related to immunological disorders. These collaborations contribute to the development of new drugs and therapies, further expanding the treatment options available to patients. The close association between hospitals and research institutes also fosters a culture of continuous learning and knowledge exchange among healthcare professionals. Hospitals & clinics hold a significant position in the Indian immunology drugs market. Their extensive reach, specialized expertise, and collaborations with research institutes and pharmaceutical companies make them pivotal in delivering effective and innovative immunology treatments to patients.

Based on region, North India is notably dominating the Indian Immunology Drugs Market due to several factors. The region's dense population, combined with various environmental and lifestyle factors, leads to a greater prevalence of immunological disorders, thereby increasing the demand for immunology drugs. This includes factors such as pollution, stress, and dietary patterns that contribute to the higher incidence of these disorders. There is a high level of healthcare infrastructure and medical facilities in this region, ensuring better access to these drugs. The presence of well-established hospitals, research centers, and pharmaceutical companies further supports the availability and distribution of immunology drugs.

Additionally, North India is home to a significant number of renowned medical professionals, including immunologists and specialists in related fields. This concentration of expertise plays a crucial role in diagnosing and treating immunological disorders effectively, thereby driving the demand for immunology drugs. The presence of affluent states in North India, with higher per capita incomes, also contributes to the higher consumption of immunology drugs. People in these states have the means to afford the cost of these treatments, ensuring wider accessibility and utilization of immunology drugs. The combination of a dense population, robust healthcare infrastructure, concentration of medical professionals, and the presence of affluent states makes North India a dominant force in the Indian Immunology Drugs Market, with increasing demand and consumption of these essential medications.


Major companies operating in India Immunology Drugs Market are:

  • Panacea Biotec Ltd.
  • Bristol-Myers Squibb India Pvt Ltd.
  • Wockhardt Ltd.
  • Pfizer Ltd.
  • Sanofi India Ltd.
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Abbott India Ltd.
  • Genetech Pvt Ltd.
  • Novartis India Ltd.
  • Allergan India Pvt Ltd.


Download Free Sample Report

Customers can also request for 10% free customization on this report.


“The India Immunology Drugs Market is anticipated to witness significant growth over the upcoming years. This is attributed to the rising incidence of immunological disorders, such as rheumatoid arthritis and multiple sclerosis, and the expanding aging population who are more susceptible to such diseases. Furthermore, increased investment in healthcare infrastructure, the presence of a robust pipeline of immunology drugs, and heightened awareness about immunological disorders are factors that are expected to drive the market.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

India Immunology Drugs Market By Drug Class (Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication, Others), By Indication (Arthritis, Plaque Psoriasis, Spondylitis, Inflammatory Bowel Disease, Transplant Rejection, Others), By End User (Hospitals & Clinics, Cancer Research Institute, Others), By Region, Competition, Forecast & Opportunities, 2019-2029F”, has evaluated the future growth potential of India Immunology Drugs Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in India Immunology Drugs Market.



Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York 10017

Tel: +1-646-360-1656

Email: [email protected]


Relevant News